Protagonist Therapeutics Advances Key Drug Candidate with European Regulatory Submission
Published on 09/14/2025 at 19:45 | Redaktion boerse-global.deProtagonist Therapeutics Inc. saw its shares close at $58.86 on Friday, registering a decline of 1.37%, despite a significant corporate development. On the same day, Johnson & Johnson submitted a marketing authorization application to the European Medicines Agency (EMA) for icotrokinra, an oral treatment for moderate-to-severe plaque psoriasis.
This European filing represents the second major regulatory step for the drug candidate, following a submission to the U.S. Food and Drug Administration (FDA) that was completed in July. Both applications are supported by a robust clinical data package derived from four separate Phase 3 trials within the ICONIC development program. The studies successfully met all primary and co-primary endpoints, demonstrating that the once-daily oral therapy offers significant skin clearance and is well-tolerated by patients.
The company’s progress was... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
